scholarly article | Q13442814 |
P356 | DOI | 10.1177/1352458517703803 |
P698 | PubMed publication ID | 28391741 |
P2093 | author name string | Jun-Ichi Kira | |
P2860 | cites work | Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis | Q28275399 |
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis | Q34300614 | ||
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. | Q34627230 | ||
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. | Q34660955 | ||
Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells | Q35441339 | ||
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod | Q35547287 | ||
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. | Q35856171 | ||
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis | Q36429919 | ||
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients | Q36792169 | ||
Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. | Q36866185 | ||
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension | Q37548575 | ||
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. | Q39770767 | ||
Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder | Q47924759 | ||
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod | Q48319736 | ||
Tumefactive multiple sclerosis lesions under fingolimod treatment | Q48350609 | ||
P433 | issue | 9 | |
P921 | main subject | neuromyelitis optica | Q611458 |
P304 | page(s) | 1300-1302 | |
P577 | publication date | 2017-04-10 | |
P1433 | published in | Multiple Sclerosis Journal | Q1952449 |
P1476 | title | Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others? | |
P478 | volume | 23 |
Q57283462 | Application of Human Induced Pluripotent Stem Cells (hiPSCs) to Study Synaptopathy of Neurodevelopmental Disorders |
Q58573155 | Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis |
Q90115095 | Dimethyl fumarate mitigates optic neuritis |
Q92854273 | Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes |
Q47096340 | Pattern Recognition of the Multiple Sclerosis Syndrome |
Q47657261 | Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping |
Q64954590 | Type 2 Inflammatory Responses in Autoimmune Demyelination of the Central Nervous System: Recent Advances. |
Search more.